Large dollar amounts, constitutional questions, and corporate responsibility are at the center of several False Claims Act lawsuits that courts will address in 2026.
Constitutional debates over the FCA’s whistleblower provisions will carry into 2026, with Janssen Products LP‘s federal appeals court challenge to a $1.6 billion damages and penalties award in an HIV drug fraud suit—among the largest awards in FCA history.
CVS Health Inc. in another case is challenging a $165 million penalty and will likely urge an appeals court to find the penalty is unwarranted, where a jury found no damages; CVS could also ask the ...
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Log in to keep reading or access research tools and resources.
Large dollar amounts, constitutional questions, and corporate responsibility are at the center of several False Claims Act lawsuits that courts will address in 2026. Constitutional debates over th...